PISANÒ, CLARISSA ANNA
 Distribuzione geografica
Continente #
NA - Nord America 466
EU - Europa 134
AS - Asia 67
Totale 667
Nazione #
US - Stati Uniti d'America 466
IT - Italia 54
CN - Cina 40
AT - Austria 32
SG - Singapore 11
GB - Regno Unito 10
PL - Polonia 10
SE - Svezia 9
ID - Indonesia 8
DE - Germania 6
UA - Ucraina 5
BE - Belgio 4
TR - Turchia 3
VN - Vietnam 3
FR - Francia 2
ES - Italia 1
FI - Finlandia 1
JP - Giappone 1
TW - Taiwan 1
Totale 667
Città #
Fairfield 71
Chandler 70
Ashburn 46
Woodbridge 35
Vienna 32
Ann Arbor 28
Houston 27
Wilmington 27
Seattle 25
Cambridge 24
Beijing 17
Ferrara 13
Princeton 13
Shanghai 11
Warsaw 10
Jacksonville 9
Jakarta 8
Milan 8
Singapore 8
Morciano Di Romagna 7
Boardman 5
Nanjing 5
Brussels 4
Cagliari 4
Monterenzio 4
Bremen 3
Dong Ket 3
Izmir 3
Norwalk 3
Nanchang 2
Pozzuoli 2
San Diego 2
Shenyang 2
Tucson 2
Zhengzhou 2
Chiswick 1
Durham 1
Falls Church 1
Ferrara di Monte Baldo 1
Florence 1
Irvine 1
Jiaxing 1
Lappeenranta 1
London 1
Mountain View 1
New Bedfont 1
Osimo 1
Pamplona 1
Philadelphia 1
Redwood City 1
Taipei 1
Tokyo 1
Vicenza 1
Washington 1
Totale 554
Nome #
Anti-Parkinsonian and anti-dyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonists 142
Safinamide differentially modulates in vivo glutamate and GABA release in the rat hippocampus and basal ganglia 124
NOP receptor ligands and Parkinson’s disease 81
Leucine-rich repeat kinase 2 (LRRK2) inhibitors differentially modulate glutamate release and Serine935 LRRK2 phosphorylation in striatal and cerebrocortical synaptosomes 78
Molecular and imaging prodromal markers of dopamine neuron degeneration in animal models of Parkinson’s disease: pathophysiology and clinical perspectives 45
Striatal and nigral muscarinic type 1 and type 4 receptors modulate levodopa-induced dyskinesia and striato-nigral pathway activation in 6-hydroxydopamine hemilesioned rats 44
Discovery and Structure-Activity Relationships of Nociceptin Receptor Partial Agonists That Afford Symptom Ablation in Parkinson's Disease Models 39
Safinamide inhibits in vivo glutamate release in a rat model of Parkinson's disease 38
Safinamide Modulates Striatal Glutamatergic Signaling in a Rat Model of Levodopa-Induced Dyskinesia 37
Therapeutic potential of RGS4 blockade in movement disorders 26
Regulator of G-Protein Signalling 4 (RGS4) negatively modulates nociceptin/orphanin FQ opioid receptor signalling: Implication for L-Dopa-induced dyskinesia 23
6-Hydroxydopamine lesion and levodopa treatment modify the effect of buspirone in the substantia nigra pars reticulata 20
Totale 697
Categoria #
all - tutte 4.718
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 428
Totale 5.146


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020125 10 2 4 9 5 15 13 15 20 9 16 7
2020/2021167 11 14 10 3 17 2 24 19 9 22 17 19
2021/202295 2 2 4 2 2 14 8 14 6 7 11 23
2022/2023171 14 26 11 22 27 24 6 5 19 0 11 6
2023/202493 8 4 4 6 8 13 4 11 2 5 4 24
Totale 697